EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieKlinische Studie (Phase III)

Safety and Efficacy of 2.5 mg and 1.25 mg Nebulized Salbutamol Compared with Placebo on Transient Tachypnea of the Newborns: A Triple-Blind Phase II/III Parallel Randomized Controlled Trial

Farhad Abolhasan Choobdar, Zahra Vahedi, Ali Mazouri, Mohammad Torkaman, Nastaran Khosravi, Nasrin Khalesi, Zahra Soltani, Arash Mohazzab, Rezvan Ashkanipour iD

Journal of Aerosol Medicine and Pulmonary Drug Delivery · 2024

DOI: 10.1089/jamp.2023.0043 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2024. Verfasst von Farhad Abolhasan Choobdar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ali-Asghar Children's Hospital, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran. Hauptthemen laut MEDLINE: Albuterol, Nebulizers and Vaporizers, Transient Tachypnea of the Newborn. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To evaluate the safety and efficacy of 2.5 and 1.25 mg nebulized salbutamol on Transient Tachypnea of the Newborn (TTN) compared with placebo.

Methods

We conducted a triple-blind, phase II/III parallel randomized controlled trial in two university-affiliated hospitals with neonatal intensive care units. Newborns with a confirmed diagnosis of TTN, with gestational age >35 weeks and gestational weight >2 kg were included. Cases of asphyxia, meconium aspiration syndrome, and persistent pulmonary hypertension were excluded. Ninety eligible patients were randomly allocated in three intervention groups (2.5 mg salbutamol, 1.25 mg salbutamol, and placebo), and a single-dose nebulized product was prescribed 6 hours after the birth. Safety outcomes included postintervention tachycardia, hyperglycemia, hypokalemia, and changes in blood pressure. To evaluate the efficacy, the duration of postintervention tachypnea, TTN clinical score, and clinical and paraclinical respiratory indices were assessed. Parents, Outcome assessors, and data analyzer were blind to the intervention.

Results

There was no adverse reaction, including tachycardia, hypokalemia, and jitteriness. Both groups of salbutamol recipients showed significant improvement regarding respiratory rate, TTN clinical score, and oxygenation indices compared with the placebo ( p -values

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbuterolNebulizers and VaporizersTransient Tachypnea of the NewbornHumansFemaleMaleInfant, NewbornTreatment OutcomeAdministration, InhalationBronchodilator AgentsIntensive Care Units, NeonatalAdrenergic beta-2 Receptor AgonistsTime FactorsDose-Response Relationship, Drug

Stichwörter der Autor:innen

respiratory outcomessafety outcomessalbutamoltachypneatransient tachypnea of the newborn

Substanzen

AlbuterolBronchodilator AgentsAdrenergic beta-2 Receptor Agonists

Autor:innen und Institutionen

  • Ali-Asghar Children's Hospital, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
  • Firooz Abadi Hospital, and School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
  • Shahid Akbar Abadi Clinical Research Development Unit (ShACRDU), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
  • Department of Pediatric, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • School of Public Health, Iran University of Medical Sciences (IUMS), Tehran, Iran.
  • Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.

ORCID-Profile: Rezvan Ashkanipour

Zitieren

APA

Choobdar, F. A., Vahedi, Z., Mazouri, A., Torkaman, M., Khosravi, N., Khalesi, N., Soltani, Z., Mohazzab, A., & Ashkanipour, R. (2024). Safety and Efficacy of 2.5 mg and 1.25 mg Nebulized Salbutamol Compared with Placebo on Transient Tachypnea of the Newborns: A Triple-Blind Phase II/III Parallel Randomized Controlled Trial. Journal of Aerosol Medicine and Pulmonary Drug Delivery. https://doi.org/10.1089/jamp.2023.0043

Vancouver

Choobdar FA, Vahedi Z, Mazouri A, Torkaman M, Khosravi N, Khalesi N, et al. Safety and Efficacy of 2.5 mg and 1.25 mg Nebulized Salbutamol Compared with Placebo on Transient Tachypnea of the Newborns: A Triple-Blind Phase II/III Parallel Randomized Controlled Trial. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2024. doi:10.1089/jamp.2023.0043

BibTeX
@article{Choobdar2024,
  author = {Choobdar, Farhad Abolhasan and Vahedi, Zahra and Mazouri, Ali and Torkaman, Mohammad and Khosravi, Nastaran and Khalesi, Nasrin and Soltani, Zahra and Mohazzab, Arash and Ashkanipour, Rezvan},
  title = {Safety and Efficacy of 2.5 mg and 1.25 mg Nebulized Salbutamol Compared with Placebo on Transient Tachypnea of the Newborns: A Triple-Blind Phase II/III Parallel Randomized Controlled Trial},
  journal = {Journal of Aerosol Medicine and Pulmonary Drug Delivery},
  year = {2024},
  doi = {10.1089/jamp.2023.0043}
}
Kostenlos starten →